IRRAS announces changes to management team

Stockholm, June 17, 2021 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Sabina Berlin will step down as Chief Financial Officer (CFO) due to personal reasons. Griffen Stapp, who currently serves as the company’s Group Financial Controller, will act as interim CFO until the search for a permanent replacement is complete. Mrs. Berlin will continue to work closely with company leadership to provide needed guidance and support during the transition period.

“Since Sabina joined IRRAS in 2014, she has been instrumental in building IRRAS into a company that is positioned for commercial acceleration,” said Kleanthis G. Xanthopoulos, Ph.D., Chief Executive Officer of IRRAS. “Working across two continents with a 9-hour time difference is very demanding, and we understand and accept her decision. We are fortunate that we have an experienced internal resource in Griffen, who has the necessary expertise to capably fill the role.”

About IRRAS

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on June 18, 2021 at 12:00 (CET).